| Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen |
| Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months | FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label... ► Artikel lesen |
| Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 | ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of ageZORYVE cream 0.3% is safe, effective, and well-tolerated for... ► Artikel lesen |
| Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen |
| Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen |
| Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen |
| MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering | ZUG, Switzerland, June 23, 2026 - MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and... ► Artikel lesen |
| MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Proposed Public Offering | ZUG, Switzerland, June 22, 2026 - MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and... ► Artikel lesen |
| MoonLake Immunotherapeutics AG: MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 | Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab's (SLK) potential best-in-class and best-in-disease profile... ► Artikel lesen |